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Introduction
Dizziness and headaches are two of the most common 
symptoms for which patients seek medical attention. 
One subtype of headache, migraines, affects at least 16% 
of the adult population. Women are more commonly af-
fected by migraines than men, especially after menarche 
[1-6]. A large percentage of individuals with migraine are 
affected by dizziness, also known as migraine-associated 
vestibulopathy (MAV) [7]. Migraine headaches and MAV 
may occur at any age [5, 8, 9]. However, patients typically 
present with a history of headaches years before vestib-
ular symptoms develop; these patients also often have a 
family history of migraine sufferers [5, 6]. In a 2007 study 
of 24 vertiginous children and 12 age-matched and sex-
matched controls, Niemensivu et al. [10] found that 10 of 
the vertiginous children had a history of migraine and 
four had migraine-associated dizziness. The authors con-
cluded that headaches and migraines were more common 
among vertiginous children than among healthy controls. 
However, clinical findings on neurological and audiolog-
ical examinations revealed no significant difference be-
tween groups.
Clinical presentation
A migraine is described as a recurring headache with vary-
ing characteristics. Migraines can present with reversible, 
focal neurological changes that may precede or coincide 
with the headache event (also known as an aura). Some pa-
tients suffering from migraines will not describe a headache 
at all, but they will instead report the associated aura-re-
lated neurological symptom, such as dizziness. The Inter-
national Headache Society (IHS) has developed a classifica-
tion system for migraines: migraine with or without aura, 
migraine with prolonged aura, basilar migraine, migraine 
aura without headache, childhood periodic syndromes, be-
nign paroxysmal vertigo of childhood, and migrainous in-
farction [11] . 
Migraine-associated vestibular symptoms may include ep-
isodic true vertigo, movement-provoked dysequilibrium, 
imbalance/unsteadiness, and complaints of lightheaded-
ness [5, 8]. Symptoms vary for each individual, and the du-
ration and frequency of vestibular symptoms may change 
over time [12]. In a 2007 retrospective review, Vuković et 
al. [13] compared the prevalence of dizziness among those 
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Abstract
Purpose of review: In the past few years, otologists have been seeing an increasing number of patients with vestibular disorders due to mi-
graine-associated vestibulopathy. This article reviews some of the latest developments in the understanding of this disease process, specifi-
cally its incidence, symptoms, diagnosis, and treatment.
Recent findings: Migraine-associated vestibular symptoms may include episodic true vertigo, movement-provoked dysequilibrium, imbalance/
unsteadiness, and complaints of lightheadedness. The pathophysiology of migraine-associated vestibulopathy is not completely understood; 
however, both peripheral and central deficits have been observed. Although the International Headache Society classification does not in-
clude migraine-associated vestibulopathy as a subclassification of migraine, there is emerging evidence to support this development, which 
should then lead toward improved diagnosis and treatment. Currently, migraine-associated vestibulopathy is still considered a diagnosis of 
exclusion.
Summary: Treatment of migraine-associated vestibulopathy is effective and includes lifestyle changes, such as reducing triggers that increase 
susceptibility to migraines (e.g. stress, poor diet, nicotine, or irregular sleep patterns), prophylactic and abortive medications, vestibular ther-
apy, or a combination of these. Further research is needed to better understand migraine-associated vestibulopathy and improve treatment.
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with and without migraines. The authors reported that 
51.7% of 327 migraine patients experienced vertigo in their 
lifetime compared with 31.5% of 324 people in the control 
group. The authors noted that vertigo symptoms coincided 
with the migraine attacks in only 23.2% of the patients. Pa-
tients with MAV also have a propensity to motion sick-
ness [14]. Although imbalance is commonly reported, few 
patients display difficulty walking without assistance [12]. 
Additionally, patients with MAV have also reported pho-
tophobia, phonophobia, and other auras, which represent a 
well established connection with migraine. Auditory symp-
toms reported in individuals with migraine-related vertigo 
include fluctuating hearing loss, tinnitus, and aura fullness, 
potentially complicating the differential diagnosis and dif-
ferentiation of the disease from Ménière’s syndrome [9,15].
Pathophysiology of migraine-associated 
vestibulopathy
The pathophysiology of MAV is not well understood. 
Both peripheral and central deficits have been observed. A 
spreading, global central nervous system depression that 
also affects the brainstem may account for central findings 
[5, 8]. Peripheral cochleovestibular dysfunction may be at-
tributed to vasospasm of the internal auditory artery caus-
ing ischemia to the labyrinth [16-18]. However, others have 
attributed central and peripheral deficits to the release of 
neurotransmitters such as calcitonin-gene-related peptide 
during the migraine attack [8]. Evidence of ion-channel 
dysfunction and calcium-channel disturbances of the inner 
ear and its central connections also offer a promising hy-
pothesis for the diagnosis and treatment of MAV [19].
Diagnosis
Dizziness may result from a variety of disease entities, in-
cluding migraines [15]. At present, although the IHS classi-
fication does not include MAV as a subclassification of mi-
graine [11], Neuhauser and Lempert [20] have proposed 
diagnostic criteria for MAV (Table 1). This may pave the 
way toward improved diagnosis and treatment. At this 
time, MAV is still considered a diagnosis of exclusion; that 
is, when no evidence exists of other peripheral or central 
nervous system disorders to account for the dizziness, this 
diagnosis is considered appropriate. The diagnostic chal-
lenge occurs because the vestibular symptoms often occur 
during headache-free periods [5, 6, 8, 21]. Specifically, one 
study [21] found that 50% of patients with vestibular symp-
toms never reported an accompanying headache.
The otoneurologic examination is typically unremarkable 
for patients with MAV. Unfortunately, there is not a single 
diagnostic test specific for MAV. However, peripheral and 
central vestibular system abnormalities noted during elec-
tronystagmography (ENG) testing (particularly caloric and 
ocular motor subtests) have been reported [22]. In a 2007 
study of the clinical features and pathophysiology of MAV, 
Celebisoy et al. [23] detected peripheral and central find-
ings on balance function tests in 35 patients. In particular, 
20% exhibited caloric unilateral weakness. Cutrer and Baloh 
[8] identified spontaneous and positional nystagmus (often 
central-type) on ENG testing. Researchers have also noted 
directional preponderance on rotational chair testing [9]. 
Patients with MAV often present symptoms in common 
with other medical diagnoses, such as Ménière’s disease 
(particularly vestibular Ménière’s). Aural fullness and fluc-
tuating hearing loss are common in patients with Ménière’s 
disease and in those patients with migraine; these similar 
auditory symptoms have led some researchers to propose 
a link between Ménière’s disease and migraines. Radtke et 
al. [24] found migraine-type symptoms in over 50% of pa-
tients with Ménière’s disease. In a 2008 study, Cha et al. 
[25*] investigated the association and pathological link be-
tween migraine, episodic vertigo, and Ménière’s disease 
in six families. In confirming this frequent association in 
closely related individuals (including identical twins), they 
then argued for the concept of heritability of a migraine-
Ménière’s syndrome. The researchers speculated that mi-
Table 1. Diagnostic criteria for migraine-associated vestibulopathy as proposed by Neuhauser and Lempert
Migrainous vertigo type  Symptoms
Definite migrainous vertigo  Recurrent episodic vestibular symptoms (moderate severity) 
 History of migraine (current or previous and meets criteria of the IHS) 
 Associated migrainous symptoms such as migrainous headache, photophobia, phonophobia, and other 
auras occurring during at least two vertiginous episodes 
 Other causes ruled out by appropriate investigations 
Probable migrainous vertigo  Recurrent episodic vestibular symptoms (moderate severity) 
 One of the following: current or previous history of migraine according to the criteria of the IHS or 
migrainous symptoms during ≥ 2 attacks of vertigo or migrainous precipitants (food triggers, sleep 
irregularities, hormonal changes) before vertigo in more than 50% of attacks or responses to migraine 
medications in more than 50% of attacks
 Other causes ruled out by appropriate investigations
Data from Neuhauser and Lempert [20]. IHS, International Headache Society.
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graine may contribute to permanent damage of the inner 
ear, subsequently predisposing the ear to Ménière’s dis-
ease. In a related retrospective case-control study, Cha et 
al. [26] compared the clinical findings of patients with Mé-
nière’s disease and migraine and patients with Ménière’s 
disease only. They discovered that the age of onset of ver-
tigo symptoms was significantly lower in patients with 
Ménière’s disease and migraine, as suggested in the 2008 
study.
Management of migraine-associated 
vestibulopathy
Research on MAV has traditionally focused on the diag-
nostic results of various balance disorders with little em-
phasis on appropriate treatment options. The appropriate 
treatment plan is similar to that for classic migraine. This 
includes lifestyle changes, such as stress reduction, nutri-
tious diet, avoiding nicotine, or avoiding irregular sleep 
patterns. In addition, the physician can also prescribe abor-
tive or prophylactic medications. Patients may also bene-
fit from vestibular therapy. In a retrospective review of the 
various management plans and their efficacy, Johnson [15] 
found that a comprehensive approach to control migraine 
headaches resulted in a substantial improvement in a ma-
jority of the patients.
Medications given for prophylaxis are often the drugs of 
choice when migraine-related vertigo attacks are severe 
and unresponsive to the nonmedical treatment options 
elucidated above [12]. Calcium-channel blockers, β-block-
ers, tri-cyclic amines, and antidepressants have all been ad-
vocated [5, 27, 28]. A prospective study by Maione [29] re-
ported either complete resolution or considerable control of 
migraine-related vertigo symptoms when combinations of 
commonly used prophylaxis medications (β-blockers, cal-
cium antagonists, and antidepressants) were administered 
in 36 patients with recurrent vertiginous spells.
Çeliker et al. [30*] investigated valproic acid to determine 
its effects on vestibular symptoms and ENG results in 37 
women who were divided into three groups: 13 patients 
with vertigo, 13 patients with nonvertigionous dizziness, 
and 11 women without any vestibular symptoms. In ENG 
evaluations performed before and after valproic acid treat-
ment, the investigators found a statistically significant de-
crease in the number of vestibular episodes in both groups 
with vertiginous symptoms. The drug was equally effec-
tive at reducing migraine headache in all groups. How-
ever, there were not any statistically significant differences 
noted on ENG. The results suggest that while the effect of 
migraine on the vestibular system may be permanent (as 
noted on ENG), valproic acid could be used to effectively 
reduce both the headache and MAV symptoms. In a 2007 
retrospective review, Iwasaki et al. [31] reported on the ef-
fectiveness of lomerizine as a prophylactic treatment of 
MAV. The calcium-channel blocker, which was adminis-
tered to 22 Japanese patients, effectively reduced headache 
and dizziness symptoms in 87% of the patients.
Conclusion
Although the IHS currently has not recognized MAV in 
the classification of migraine, there is emerging clinical ev-
idence to support this diagnosis. The relationship between 
vestibular symptoms and migraine is commonly observed. 
However, further research, involving multidisciplinary and 
multicenter approaches, is needed to better understand the 
pathophysiologic mechanisms behind MAV. Ultimately, 
this will result in the earlier diagnosis and improved treat-
ment of patients with MAV.
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